Endothelin-1 (ET-1) is a potent bioactive mediator that induces vasoconstriction and promotes vascular remodeling. Previous studies indicate that ET-1 plays an important role in the pathophysiology of humans. This includes various cardiovascular and renal complications.

Some humans with chronic heart failure might also have chronic renal failure.

The organ damage in heart and kidneys increases with age. While symptoms of organ damage will vary according to the affected organ, the patient will likely need special management, including a restricted diet and/or a therapeutic.

The ET-traps, a patented technology, are a novel molecular construct, which has been shown to significantly sequester the increased levels of ET-1 found in different disease states. ET-traps have been found to be a potential therapeutic for ameliorating different pathologies related to elevate ET-1 levels, such as disruptions in the heart and kidney functions. Hence, the ET-traps could effectively tackle serious health conditions associated with disruptions in the endothelin system. This paper discusses the potential application of ET-traps as a therapeutic for use in human complications of the heart and kidneys.